C4 Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
08/05/2024 14:52
* C4 Therapeutics Inc CCCC.OQ reported a quarterly
adjusted loss
of 41 cents per share for the quarter ended in January, higher
than the same quarter last year, when the company reported EPS
of -71 cents. The mean expectation of seven analysts for the
quarter was for a loss of 35 cents per share. Wall Street
expected results to range from -60 cents to -18 cents per share.
* Revenue fell 19.2% to $3.04 million from a year ago;
analysts
expected $8.10 million.
* C4 Therapeutics Inc's reported EPS for the quarter was a
loss
of 41 cents.
* The company reported a quarterly loss of $28.36 million.
* C4 Therapeutics Inc shares had fallen by 16.9% this
quarter and
gained 20.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 34.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for C4 Therapeutics
Inc is $13.50
This summary was machine generated from LSEG data May 8 at 01:51
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.35 -0.41 Missed
Dec. 31 2023 -0.68 -0.70 Missed
Sep. 30 2023 -0.66 -0.52 Beat
Jun. 30 2023 -0.69 -0.73 Missed